[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-374364-105":59,"doc-detail-374364-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mapping-breast-cancer-therapy-with-circulating-tumor-cells-the-expert-perspective-review-focus-on-ctc-enumeration-and-phenotyping","Mapping breast cancer therapy with circulating tumor cells: The expert perspective - Review focus on CTC enumeration and phenotyping","","Circulating tumor cells (CTCs) serve as a key prognostic biomarker in breast cancer, especially in metastatic disease where a threshold of ≥5 CTCs per 7.5 mL of blood correlates with poorer survival and aggressive stage IV behavior, while fewer than five indicates a less aggressive, stage IV indolent course. Molecular CTC profiling provides a real-time view of tumor biology and variability. Beyond prediction, CTCs can support treatment-intensity decisions in clinical trials, and the review evaluates how CTC-guided strategies and integration with biomarkers like ctDNA may enhance personalized therapy and trial design.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mapping-breast-cancer-therapy-with-circulating-tumor-cells-the-expert-perspective-review-focus-on-ctc-enumeration-and-phenotyping/374364/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mapping-breast-cancer-therapy-with-circulating-tumor-cells-the-expert-perspective-review-focus-on-ctc-enumeration-and-phenotyping/374364.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How are circulating tumor cells (CTCs) used to stratify metastatic breast cancer prognosis?","Question",{"text":113,"@type":114},"CTC levels of ≥5 per 7.5 mL of blood are linked to poorer survival and aggressive stage IV disease, whereas fewer than five per 7.5 mL indicates less aggressive, stage IV indolent disease.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does molecular characterization of CTCs add beyond simple enumeration?",{"text":118,"@type":114},"Molecular CTC characterization provides a real-time snapshot of tumor biology, capturing temporal and spatial variability and offering insights into tumor behavior.",{"name":120,"@type":111,"acceptedAnswer":121},"How can CTCs guide treatment intensity in clinical settings?",{"text":122,"@type":114},"CTCs can be used to tailor treatment intensity, as explored in clinical trials such as the STIC trial, and may be combined with other liquid biopsy biomarkers like circulating tumor DNA.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},374364,1790630870,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","The Breast 81 (2025) 104463  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Mapping breast cancer therapy with circulating tumor cells: The expert perspective |  |  | |\n| --- | --- | --- | --- |\n| Lorenzo Gerratanaa,b,1, Caterina Gianni c,d,1, Eleonora Nicol`o c, Letizia Pontolillo c,e, Francois-Clement Bidard f, Carolina Reduzzic,* , Massimo Cristofanillic\u003Cbr>a Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy\u003Cbr>b Department of Medicine, University of Udine, Udine, Italy\u003Cbr>c Liquid Biopsy Platform, Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA d Medical Oncology and Breast Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Forlì-Cesena, Italy e Department of Translational Medicine and Surgery, Universita’ Cattolica Del Sacro Cuore, Rome, Italy\u003Cbr>f Department of Medical Oncology, Institute Curie, UVSQ University, Paris & St Cloud, France |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Breast cancer Circulating tumor cells Precision medicine Liquid biopsy |  | Circulating tumor cells (CTCs) have emerged as a key prognostic biomarker for breast cancer, with their role becoming more pronounced in metastatic cases. In metastatic breast cancer, having five or more CTCs per 7.5 mL of blood is linked to poorer survival and more aggressive disease, marking it as stage IV aggressive. Conversely, fewer than five CTCs per 7.5 mL of blood indicates a less aggressive, stage IV indolent disease. Additionally, molecular CTCs characterization provides a real-time snapshot of tumor biology, capturing its temporal and spatial variability and providing insights into tumor behavior.\u003Cbr>Beyond their role in predicting outcomes, CTCs can help guide treatment intensity as shown in clinical trials like the STIC trial, offering a new way to tailor therapy alongside other liquid biopsy biomarkers such as circulating tumor DNA.\u003Cbr>The aim ofour review is to focus on both enumeration and phenotyping ofCTCs and examine how CTC-guided strategies can improve treatment tailoring and patient outcomes. We also explore the potential for integrating CTCs with other biomarkers, such as circulating tumor DNA, and discuss how innovative biomarker-driven clinical trial designs could further advance personalized treatment strategies. |  |\n\n1. Introduction  \nOver the past 20 years, circulating tumor cells (CTCs) have become an established prognostic biomarker for patients with breast cancer (BC). Their role in disease monitoring has expanded, especially after the Food and Drug Administration (FDA) approved the CellSearch® system (Menarini-Silicon Biosystems, Huntingdon Valley, PA) as semiautomated platform for detecting CTCs in patients with metastatic BC (MBC). This approval was supported by multiple prospective and retrospective evidence all demonstrating that CTC count offers insights into disease behavior, distinguishing between stage IV aggressive (≥5 CTCs/7.5 mL) and stage IV indolent (\u003C5 CTCs/7.5 mL) [1–3]. These subgroups are characterized by specific outcomes, with higher CTC count  \nassociated to worse prognosis, independent of other clinic-pathological characteristics [2]. Although less frequently detected in patients with early breast cancer (EBC), CTCs still hold prognostic significance in this population, as a lower threshold of ≥1 CTCs/7.5 mL of blood has been proposed for prognostication [4].  \nBeyond their prognostic role, CTCs can be utilized to guide treatment intensity in patients with BC. Here we provide an overview, focusing on both enumeration and phenotyping, and explore how CTC-guided strategies can improve treatment tailoring and patient outcomes. We also discuss the potential for integrating CTCs with other biomark","cbCaitcKPCWjSdlu","https://ap.wps.com/l/cbCaitcKPCWjSdlu","pdf",1028967,"English","# Contents lists available at ScienceDirect\n## The Breast\n## Mapping breast cancer therapy with circulating tumor cells: The expert perspective\n## A R T I C L E I N F O\n## A B S T R A C T\n## 1. Introduction\n## 2. CTC enumeration as a biomarker in clinical trials: from dynamic response assessment to prediction","[{\"question\":\"How are circulating tumor cells (CTCs) used to stratify metastatic breast cancer prognosis?\",\"answer\":\"CTC levels of ≥5 per 7.5 mL of blood are linked to poorer survival and aggressive stage IV disease, whereas fewer than five per 7.5 mL indicates less aggressive, stage IV indolent disease.\"},{\"question\":\"What does molecular characterization of CTCs add beyond simple enumeration?\",\"answer\":\"Molecular CTC characterization provides a real-time snapshot of tumor biology, capturing temporal and spatial variability and offering insights into tumor behavior.\"},{\"question\":\"How can CTCs guide treatment intensity in clinical settings?\",\"answer\":\"CTCs can be used to tailor treatment intensity, as explored in clinical trials such as the STIC trial, and may be combined with other liquid biopsy biomarkers like circulating tumor DNA.\"}]","Mapping breast cancer therapy with circulating tumor cells: The expert perspective - Review focus on CTC enumeration and phenotyping | PDF",1790201522,15]